Leadership Team Expansion - Solaris Resources Inc has strengthened its leadership team with the appointment of Richard Hughes as Chief Financial Officer and Company Secretary, Patrick Chambers as Vice President Investor Relations, and Ignacio Shimamoto as Vice President Finance, effective immediately [1] - Richard Hughes, with over 20 years in the natural resources sector, will lead the finance function leveraging his recent experience as CFO and Executive Director of Trident Royalties PLC, which was recently acquired [2] - Patrick Chambers will drive global investor engagement, leveraging his strong geological, investor relations, and business development background, with a focus on Latin America [2] - Ignacio Shimamoto will lead financial strategy, focusing on enhancing operational efficiency, strengthening compliance, and supporting the company's growth through strategic planning, financial oversight, and valuations of projects and investments [2] New Appointments Background - Richard Hughes has over 20 years of experience in the natural resources sector, with significant knowledge across strategy, capital markets, and corporate finance, and most recently served as CFO and Executive Director of Trident Royalties PLC [4] - Patrick Chambers is a metals and mining investor relations professional with an extensive track record across a range of commodities, focusing on Latin America, and most recently served as Head of Investor Relations at Horizonte Minerals [6] - Ignacio Shimamoto is a senior finance executive with over 20 years of experience in financial planning, business improvement, acquisitions, and cost optimization within the natural resources sectors, having served as Finance Manager for Copper Peru at Glencore [7][8] Company Overview - Solaris Resources Inc is a copper-gold exploration and development company, committed to a sustainable future through participatory and responsible mining [10] - The Warintza Project, a large copper-gold porphyry deposit, has a disclosed resource endowment of over 2.3 billion tonnes and is located in southeast Ecuador [10] - The company also owns a series of grassroots exploration projects with discovery potential in Peru and Chile, and a 60% interest in the La Verde joint-venture project with a subsidiary of Teck Resources in Mexico [10] Final Emigration Steps - The company announces that the final emigration steps are now complete, subject to a few administrative matters [9]

Core Insights - SELLAS Life Sciences Group, Inc. announced high efficacy of SLS009, a selective CDK9 inhibitor, in solid cancers with ASXL1 mutations, showing a response rate of 67% compared to 0% in non-mutated cancers [1][5] - ASXL1 mutations were identified as a predictive biomarker for SLS009 efficacy in colorectal cancer (CRC MSI-H) and non-small cell lung cancer (NSCLC) [1][2] - The company has filed for provisional patent protection for the use of ASXL1 mutations as a predictive diagnostic tool for selecting cancer patients likely to benefit from SLS009 [5] Summary by Sections Efficacy of SLS009 - In preclinical studies, SLS009 demonstrated high efficacy (IC50 < 100 nM) in 67% of ASXL1 mutated solid cancer cell lines, while no efficacy was observed in non-ASXL1 mutated lines [4][5] - In CRC MSI-H, 57% of ASXL1 mutated cell lines showed high efficacy, while none of the non-mutated lines responded [4] - In NSCLC, 100% of ASXL1 mutated cell lines exhibited high efficacy, with no response in non-mutated lines [4] ASXL1 Mutations in Solid Cancers - ASXL1 mutations were found in 58% of CRC MSI-H patient-derived cell lines and 33% of NSCLC cell lines, exceeding predicted frequencies [4] - Overall, ASXL1 mutations were recorded in 9 out of 18 studied solid cancer cell lines [4] Clinical Development and Future Prospects - The findings support the development of targeted therapies for solid tumors based on ASXL1 mutation status [5] - The company aims to leverage existing clinical data demonstrating SLS009's efficacy in acute myeloid leukemia (AML) to strengthen its position in solid cancers [5][6]

– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML After Venetoclax Failure to be Presented at the Upcoming American Society of Hematology (ASH) Annual Meeting in December – – GPS Granted FDA Rare Pediatric Disease Designation (RPDD) for the Treatment of Pediatric AML – NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, I ...

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 at 9:00 am EDT. Maxim Healthcare Virtual Summit Details: ...

-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinicalstage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the signing of a Material Transfer Agreement (MTA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) to supply SLS-002 (intranasal racemic ketamine) for the U.S. Department of Defense ...

Galena Biopharma, Inc. (SLS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The ...

- Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 - - Reported Positive Preliminary Data from the Phase 2a Trial of SLS009 in r/r AML Demonstrating to Date Overall Response Rate (ORR) of 33%, 50%, and 100% in 60 mg QW, 30 mg BIW and 30mg BIW with ASXL1 Mutation Cohorts Respectively - - SLS009 Granted EMA Orphan Drug Designations and U.S. FDA ...

Core Insights - SELLAS Life Sciences Group, Inc. has received Orphan Drug Designation from the European Medicines Agency for SLS009, a selective CDK9 inhibitor targeting relapsed/refractory peripheral T-cell lymphomas [1][2] - The company has previously obtained Orphan Drug and Fast Track Designations from the FDA for SLS009, indicating strong regulatory recognition [2] - SLS009 has shown a 36.4% response rate in PTCL patients during Phase 1 trials, outperforming the current standard of care, belinostat, which has a 25.8% response rate [2] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [4] - The company’s other lead product candidate, GPS, targets the WT1 protein and has potential applications in both hematologic malignancies and solid tumors [4] - SLS009 is positioned as a potentially first and best-in-class CDK9 inhibitor, with reduced toxicity and increased potency compared to existing options [4]

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for SLS009, a novel, and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL). "We are pleased t ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 15,849,056 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggr ...